ScholarX: Browsing ScholarWorks

Browsing by Majem, M[Majem, Margarita]Author

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

전체 가 나 다 라 마 바 사 아 자 차 카 타 파 하

Sort by: In order: Results/Page Authors/Record:

Showing results 1 to 9 of 9

SCIESCOPUS

Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC

Herbst, RS[Herbst, Roy S.]; Baas, P[Baas, Paul]; Perez-Gracia, JL[Perez-Gracia, Jose Luis]; Felip, E[Felip, Enriqueta]; Kim, DW[Kim, Dong-Wan]; Han, JY[Han, Ji-Youn]; Molina, JR[Molina, Julian R.]; Kim, JH[Kim, Joo-Hang]; Arvis, CD[Arvis, Catherine Dubos]; Ahn, MJ[Ahn, Myung-Ju], et al.

ArticleIssue Date2016CitationJOURNAL OF CLINICAL ONCOLOGY, v.34, no.15PublisherAMER SOC CLINICAL ONCOLOGY

SCIESCOPUS

Factors associated with better overall survival (OS) in patients with previously treated, PD-L1-expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010.

Herbst, RS[Herbst, Roy S.]; Baas, P[Baas, Paul]; Kim, DW[Kim, Dong-Wan]; Felip, E[Felip, Enriqueta]; Perez-Gracia, JL[Perez-Gracia, Jose Luis]; Han, JY[Han, Ji-Youn]; Molina, JR[Molina, Julian R.]; Kim, JH[Kim, Joo-Hang]; Dubos, C[Dubos, Catherine]; Ahn, AMJ[Ahn, Arvis Myung-Ju], et al.

ArticleIssue Date2017CitationJOURNAL OF CLINICAL ONCOLOGY, v.35PublisherAMER SOC CLINICAL ONCOLOGY

SCIESCOPUS

KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.

Wakelee, HA[Wakelee, Heather A.]; Liberman, M[Liberman, Moishe]; Kato, T[Kato, Terufumi]; Tsuboi, M[Tsuboi, Masahiro]; Lee, SH[Lee, Se-Hoon]; He, J[He, Jie]; Gao, SG[Gao, Shugeng]; Chen, KN[Chen, Ke-Neng]; Dooms, CA[Dooms, Christophe Alfons]; Majem, M[Majem, Margarita], et al.

ArticleIssue Date2023CitationJOURNAL OF CLINICAL ONCOLOGY, v.41, no.17PublisherLIPPINCOTT WILLIAMS & WILKINS

SCIESCOPUS

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Herbst, RS[Herbst, Roy S.]; Baas, P[Baas, Paul]; Kim, DW[Kim, Dong-Wan]; Felip, E[Felip, Enriqueta]; Perez-Gracia, JL[Perez-Gracia, Jose L.]; Han, JY[Han, Ji-Youn]; Molina, J[Molina, Julian]; Kim, JH[Kim, Joo-Hang]; Arvis, CD[Arvis, Catherine Dubos]; Ahn, MJ[Ahn, Myung-Ju], et al.

ArticleIssue Date2016CitationLANCET, v.387, no.10027, pp.1540 - 1550PublisherELSEVIER SCIENCE INC

SCIESCOPUS

Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%; Results from KEYNOTE-010.

Garon, EB[Garon, Edward B.]; Herbst, RS[Herbst, Roy S.]; Kim, DW[Kim, Dong-Wan]; Felip, E[Felip, Enriqueta]; Perez-Gracia, JL[Perez-Gracia, Jose Luis]; Han, JY[Han, Ji-Youn]; Kim, JH[Kim, Joo-Hang]; Arvis, CD[Arvis, Catherine Dubos]; Ahn, MJ[Ahn, Myung-Ju]; Majem, M[Majem, Margarita], et al.

ArticleIssue Date2016CitationJOURNAL OF CLINICAL ONCOLOGY, v.34, no.15PublisherAMER SOC CLINICAL ONCOLOGY

SCIESCOPUS

Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment

Herbst, RS[Herbst, Roy S.]; Baas, P[Baas, Paul]; Perez-Gracia, JL[Perez-Gracia, Jose L.]; Felip, E[Felip, Enriqueta]; Kim, DW[Kim, Dong-Wan]; Han, JY[Han, Ji-Youn]; Molina, J[Molina, Julian]; Kim, JH[Kim, Joo-Hang]; Arvis, CD[Arvis, Catherine Dubos]; Ahn, MJ[Ahn, Myung-Ju], et al.

ArticleIssue Date2016CitationJOURNAL OF THORACIC ONCOLOGY, v.11, no.10, pp.S174 - S175PublisherELSEVIER SCIENCE INC

SCIESCOPUS

Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment

ArticleIssue Date2016CitationJOURNAL OF THORACIC ONCOLOGY, v.11, no.10, pp.S242 - S243PublisherELSEVIER SCIENCE INC

SCIESCOPUS

Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer

Wakelee, H[Wakelee, Heather]; Liberman, M[Liberman, Moishe]; Kato, T[Kato, Terufumi]; Tsuboi, M[Tsuboi, Masahiro]; Lee, SH[Lee, Se-Hoon]; Gao, SG[Gao, Shugeng]; Chen, KN[Chen, Ke-Neng]; Dooms, C[Dooms, Christophe]; Majem, M[Majem, Margarita]; Eigendorff, E[Eigendorff, Ekkehard], et al.

ArticleIssue Date2023CitationNEW ENGLAND JOURNAL OF MEDICINE, v.389, no.6, pp.491 - 503PublisherMASSACHUSETTS MEDICAL SOC

SCIESCOPUS

Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1-Positive NSCLC.

Baas, P[Baas, Paul]; Garon, EB[Garon, Edward B.]; Herbst, RS[Herbst, Roy S.]; Felip, E[Felip, Enriqueta]; Perez-Gracia, JL[Perez-Gracia, Jose Luis]; Han, JY[Han, Ji-Youn]; Molina, JR[Molina, Julian R.]; Kim, JH[Kim, Joo-Hang]; Arvis, CD[Arvis, Catherine Dubos]; Ahn, MJ[Ahn, Myung-Ju], et al.

ArticleIssue Date2016CitationJOURNAL OF CLINICAL ONCOLOGY, v.34, no.15PublisherAMER SOC CLINICAL ONCOLOGY

STATISTICS: Total View:; Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Browsing by Majem, M[Majem, Margarita]Author

BROWSE